Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADAPTIN BIO, INC.NONE · Entity 9083 | Chief Financial Officer | September 08, 2025 | September 10, 2025 |
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | Chief Accounting Officer | September 09, 2019 | September 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADAPTIN BIO, INC.
Report date September 08, 2025 · Filed September 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2035-09-07 | Direct | 192,231 |
Reported balance
After 2025-09-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-08 · Grant · Acquired 192,231 · Balance 192,231 F1: 50% of the stock option vested on September 8, 2025. The remaining 50% of the stock option vests in equal monthly installments on the last day of each calendar month over 48 months, beginning on September 8, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the stock option vested on September 8, 2025. The remaining 50% of the stock option vests in equal monthly installments on the last day of each calendar month over 48 months, beginning on September 8, 2025.
Milestone Pharmaceuticals Inc.
Report date September 09, 2019 · Filed September 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.45 · Expires 2029-09-09 | Direct | 20,000 |
Reported balance
After 2019-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-09-09 · Grant · Acquired 20,000 · Balance 20,000 F1: One-fourth (1/4th) of the shares subject to the option vest on September 9, 2020 and one forty-eighth (1/48th) of the shares subject to the option vest on each one month anniversary thereafter, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4th) of the shares subject to the option vest on September 9, 2020 and one forty-eighth (1/48th) of the shares subject to the option vest on each one month anniversary thereafter, subject to the Reporting Person continuing to provide service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2025 Filed Sep 10, 2025 20:59 UTC | ADAPTIN BIO, INC. NONE · Entity 9083 | GrantStock Option (right to buy) · Derivative | 192,231 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001213900-25-086581 · marketforms-70721.xml · derivative · entry 1 Maness Timothy · CIK 0001774294 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,231 Underlying: Common Stock · 192,231 shares Expires 2035-09-07 F1 · derivative.exercise_date: 50% of the stock option vested on September 8, 2025. The remaining 50% of the stock option vests in equal monthly installments on the last day of each calendar month over 48 months, beginning on September 8, 2025. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 21:30 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $22.45 | $0.00 |
DisclosureSEC source: 0001209191-19-049211 · doc4.xml · derivative · entry 1 Maness Timothy · CIK 0001774294 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2029-09-09 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on September 9, 2020 and one forty-eighth (1/48th) of the shares subject to the option vest on each one month anniversary thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 08, 2019 Filed May 9, 2019 20:57 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantEmployee Stock Option (right to buy) · Derivative | 46,998 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-19-028517 · doc4.xml · derivative · entry 1 Maness Timothy · CIK 0001774294 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,998 Underlying: Common Shares · 46,998 shares Expires 2029-05-08 F1 · derivative.exercise_date: One-fourth (1/4th) of the share subject to the option vest on April 11, 2020 and one forty-eighth (1/48th) of the shares subject to the option vest on each one month anniversary thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.